Paid Clinical Trials New Mexico
Discover 411 paid clinical trials in New Mexico. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Is the Degree of Perceived Effort During Resistance Exercise Important for Improvements in Blood GlucoseIs the Degree of Perceived Effort During Resistance Exercise Important for Improvements in Blood Glucose
Sponsor:
University of New Mexico
Location:
Code:
NCT06208189
Conditions
PreDiabetes
Type 2 Diabetes Mellitus
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
High-effort session
Low-effort session
Control
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLCTo Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Sponsor:
Shanghai Henlius Biotech
Location:
Code:
NCT05468489
Conditions
Extensive Stage Small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Serplulimab + chemotherapy (carboplatin-etoposide)
Atezolizumab + chemotherapy (carboplatin-etoposide)
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Sponsor:
Hoffmann-La Roche
Location:
Code:
NCT06065748
Conditions
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Giredestrant
Fulvestrant
Abemaciclib
Palbociclib
Ribociclib
Mindfulness for Alcohol Abusing OffendersMindfulness for Alcohol Abusing Offenders
Sponsor:
The Mind Research Network
Location:
Code:
NCT03883646
Conditions
Alcohol Abuse
Criminal Behavior
Eligibility Criteria
Sex: Female
Age: 18 - 65
Healthy Volunteers: Not accepted
Interventions
Mindfulness
Relapse Prevention
PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening IschemiaPROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
Sponsor:
LimFlow, Inc.
Location:
Code:
NCT05313165
Conditions
Critical Limb Ischemia
Chronic Limb-Threatening Ischemia
Peripheral Arterial Disease
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
LimFlow Stent Graft System
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental VitiligoA 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
Sponsor:
Pfizer
Location:
Code:
NCT06163326
Conditions
Vitiligo
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Ritlecitinib
Ritlecitinib 100 mg
Placebo
A Behavioral Intervention to Promote Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial HyperplasiaA Behavioral Intervention to Promote Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia
Sponsor:
Washington University School of Medicine
Location:
Code:
NCT05903131
Conditions
Endometrial Hyperplasia
Grade 1 Endometrial Cancer
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Telemedicine behavioral weight intervention
Progestin
Enhanced usual care
Levonorgestrel-releasing IUD.
Enlighten Study: The EV-ICD Post Approval RegistryEnlighten Study: The EV-ICD Post Approval Registry
Sponsor:
Medtronic
Location:
Code:
NCT06048731
Conditions
Ventricular Arrhythmia
Tachycardia
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Defibrillation using EV-ICD
FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Sponsor:
Fusion Pharmaceuticals Inc.
Location:
Code:
NCT06402331
Conditions
Metastatic Castration-resistant Prostate Cancer
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Not accepted
Interventions
FPI-2265